drugset / Trial / NCT01313312

Dysport® Adult Upper Limb Spasticity Extension Study

NCT01313312 ↗

Phase 3 Completed 258 enrolled Ipsen
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.

Timeline

Start
2011-11
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 500 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 1000 iu Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 1500 iu Intramuscular